Less than a tenth of individuals that would benefit from obesity jabs such as Wegovy are able to get them, warns the World Health Organization as it issues its initial advice on the medications.
Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for more widespread and fairer access to this class of drugs.
Based on estimates, over two billion could be living with obesity by 2030 if no action is taken.
"The latest guidelines acknowledges that obesity is a long-term condition that can be treated with thorough and ongoing treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key hurdles to universal access to the jabs that can help people shift substantial weight, notes the organization.
GLP-1 Therapy Scarcity
Even under the present most optimistic outlook, the supply of GLP-1 therapies might only reach approximately 100 million people – under 10% of those who need them, according to the WHO.
The guideline calls on governments and firms to widen availability, through approaches including voluntary licensing.
A patent on the active ingredient – the primary component of a leading brand – is due to expire in multiple nations in 2026.
The Way Obesity Drugs Function
The injections replicate a biological compound to slow digestion, reduce hunger and enhance the sense of being full so individuals consume fewer calories.
People commonly see weight reduction after several weeks of starting on the regular doses.
Research suggests people may put most of the weight back on after a year of discontinuing the treatment, because their usual hunger resume.
Being above a healthy weight increases your chance for experiencing diseases, such as diabetes, cardiovascular issues, stroke, and some cancers.
Obesity concerns individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, per the WHO.
